5F-203

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H11FN2S
Molecular Weight	258.314
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(=CC=C1N)C2=NC3=C(S2)C=CC(F)=C3

InChI

InChIKey=IFWLHIIUGSEKKE-UHFFFAOYSA-N

InChI=1S/C14H11FN2S/c1-8-6-9(2-4-11(8)16)14-17-12-7-10(15)3-5-13(12)18-14/h2-7H,16H2,1H3

HIDE SMILES / InChI

Molecular Formula	C14H11FN2S
Molecular Weight	258.314
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15377855 | https://www.ncbi.nlm.nih.gov/pubmed/15634650
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800021353

5F-DF-203-L-LYSINAMIDE (Phortress) is an experimental antitumor agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal origin. The mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumors only. Phortress is in phase I clinical trials for the treatment of solid tumours. The compound was co-developed by Pharminox, University of Nottingham and Cancer Research UK.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Aryl Hydrocarbon Receptor Pathway 4 Target ID: WP2873 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23696052	Activator 1447
Oxidative Stress 162 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23696052	Activator 1447
NIK/NF-kappaB signaling 9 Target ID: GO:0038061 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15655410	Activator 1447
DNA 282 Target ID: CHEMBL2311221 Sources: http://adisinsight.springer.com/drugs/800021353 \| https://www.ncbi.nlm.nih.gov/pubmed/23143926 \| https://www.ncbi.nlm.nih.gov/pubmed/15634650	Crosslinking Agent 83
Cytochrome P450 1A1 32 Target ID: CHEMBL2231 Sources: http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html \| http://adisinsight.springer.com/drugs/800021353 \| https://www.ncbi.nlm.nih.gov/pubmed/12592376 \| https://www.ncbi.nlm.nih.gov/pubmed/15377855	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html http://adisinsight.springer.com/drugs/800021353	Primary		Phase I 438	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
2.31 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497	10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PHORTRESS plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.27 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497	10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		PHORTRESS plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
3.239 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497	10 mg/kg single, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		PHORTRESS plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
5.415 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19088497	10 mg/kg 1 times / week multiple, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered:		PHORTRESS plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

PubMed

Title	Date	PubMed
The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.	2004-09	15377855

Patents

Sample Use Guides

In Vivo Use Guide

50 patients were treated with 145 cycles of 5F-DF-203-L-LYSINAMIDE (Phortress) over a dose range of 3-50mg/m2. The first 6 patients were treated on d1,8 Q4weeks, 2 patients having DLTs. The protocol was amended to d1 q3weekly dosing, and escalated from 3 to 50 mg/m2 over 10 cohorts.

Route of Administration: Intravenous

In Vitro Use Guide

5F-DF-203-L-LYSINAMIDE caused a concentration-dependent cytokine response in precision-cut lung slice (PCLS) model. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE modestly elevated TNF-α within 24h, with average levels of TNF-α in PCLS reaching 25 pg/mg, just above assay LLOD. Exposure to 25uM 5F-DF-203-L-LYSINAMIDE for 72h increased tissue levels of IL-β, IL-5, and CINC. Exposure to 50 and 100uM caused significant increases in PCLS content for all six cytokines analyzed.

Substance Class	Chemical Created by `admin` on `Tue Apr 01 21:35:15 GMT 2025` Edited by `admin` on `Tue Apr 01 21:35:15 GMT 2025`
Record UNII	3J3GHW53E4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

5F-203

Code

English

NSC-703786

Preferred Name

English

BENZENAMINE, 4-(5-FLUORO-2-BENZOTHIAZOLYL)-2-METHYL-

Common Name

English

2-(4-AMINO-3-METHYLPHENYL)-5-FLUOROBENZOTHIAZOLE

Common Name

English

5F203

Code

English

4-(5-FLUOROBENZO(D)THIAZOL-2-YL)-2-METHYLANILINE

Systematic Name

English

Code System Code Type Description

NSC

703786